Cancer Stock Moving Higher - GTX Inc

Shares of GTX Inc skyrocketed 34.55% to $3.7 per share as Citigroup analysts upgrade the rating of the stock from Hold to Buy.  The company makes small molecules that selectively target hormone pathways to prevent and treat cancer, fractures and bone loss, muscle loss and other serious medical conditions. Since the company is in the lucrative cancer market with one drug on the market for breast cancer treatment and one other at stage III of the clinical trial for prostate cancer and 4 other on the pipeline, expect more future growth to come.  The stock is now near 52 weeks high so expect resistance at this point.